| abstract |
Without limitation, the present disclosure relates to methods for treating cell proliferation disorders, neoplastic disorders, cancer, tumors, etc. using anti-IGF antibodies, or antigen-binding fragments thereof. Disclosed herein is a method of treating cancer in a patient, eg, a patient such as a human patient, wherein the method includes at least two doses of an antibody that binds to both IGF-I and / or IGF-II to the patient. Administering. These doses are about 1 week or about 3 weeks apart and each dose comprises an amount of antibody greater than about 0.5 mg kg patient body weight and less than about 50 mg / kg patient body weight. [Selection] Figure 1A |